FQ
CORT icon

First Quadrant’s Corcept Therapeutics CORT Stock Holding History

First Quadrant’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,200
Closed -$24K – 230
2021
Q4 		$24K Buy
+1,200
New +$24.3K ﹤0.01% 462
2019
Q4 		– Sell
-19,600
Closed -$277K – 579
2019
Q3 		$277K Buy
+19,600
New +$241K 0.03% 372
2018
Q2 		– Sell
-2,115
Closed -$35K – 771
2018
Q1 		$35K Hold
2,115
– – ﹤0.01% 761
2017
Q4 		$38K Hold
2,115
– – ﹤0.01% 857
2017
Q3 		$41K Sell
2,115
-691
-25% -$10.3K ﹤0.01% 852
2017
Q2 		$33K Sell
2,806
-2,328
-45% -$25.3K ﹤0.01% 846
2017
Q1 		$56K Buy
+5,134
New +$45.1K ﹤0.01% 741

Other funds holding CORT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

First Quadrant's CORT Position: Q1 2022 in Review

First Quadrant sold out of Corcept Therapeutics (CORT) in Q1 2022, closing a stake of 1,200 shares — an estimated $24K sold.

First Quadrant first reported a position in CORT in Q1 2017 and held it in 7 quarters. The position peaked at $277K in Q3 2019. 228 funds tracked by Wall St. Rank hold CORT as of Q1 2022.

  • First Quadrant reported no remaining Corcept Therapeutics position as of Q1 2022 after selling out during the quarter.
  • First Quadrant sold 1,200 Corcept Therapeutics shares in Q1 2022, an estimated $24K.
  • First Quadrant first reported a position in Corcept Therapeutics in Q1 2017 and held it in 7 quarters.
  • First Quadrant's Corcept Therapeutics position peaked at $277K in Q3 2019.
  • 228 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2022.

Based on First Quadrant's 13F filing for Q1 2022, filed 21 Apr 2022.